Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "IDARUBICIN HYDROCHLORIDE FOR INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"IDARUBICIN HYDROCHLORIDE FOR INJECTION" OBTAINS

APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Idarubicin Hydrochloride for Injection" (brand name: Anbijian (安必健)) (including two specifications of 5mg and 10mg), a drug for the treatment of Acute Myeloid Leukemia ("AML") developed by the Group, has obtained approval for drug registration granted by the National Medical Products Administration of the People's Republic of China and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Idarubicin is a fundamental treatment drug for AML unanimously recommended by domestic and foreign guidelines. Anbijian developed by the Group is the first product of its kind in the PRC that has passed the Consistency Evaluation, with advanced formulation technique, excellent product quality, and good efficacy and safety. The approval for launch of this product further enriches the product portfolio of the Group in the field of hematoma and solidifies the Group's competitive position in this field.

AML is a malignant tumor with high aggression and rapid progression. If left untreated, the patient will suffer from infection or death from haemorrhage within a few months after diagnosis. The IA (3+7) regimen consisting of Idarubicin combined with Cytarabine (Ara-C) is the standard first-line regimen for the treatment of AML, which plays a fundamental role in reducing or eliminating residual disease and prolonging survival. Among them, Idarubicin is an anti-tumor antibiotic with unique chemical structure as well as high fat solubility and antitumor activity, and is a material component of the classic treatment regimen. It has been clinically proven that Idarubicin can be used in AML patients of different age groups and different risk stratifications and is a guarantee of high remission rate and long survival period. The clinical practice guidelines of the National Comprehensive Cancer Network (NCCN) recommended Idarubicin for the whole process for the treatment of AML. The successful launch of Anbijian will provide more patients with better choices.

1

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 29 July 2020

As at the date of this announcement, the Board of the Company comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2